Aarey Drugs & Pharmaceuticals Limited (NSE:AAREYDRUGS)
India · Delayed Price · Currency is INR 56.39
+2.68 (4.99%)
Apr 6, 2026, 3:28 PM IST
NSE:AAREYDRUGS Revenue
Aarey Drugs & Pharmaceuticals had revenue of 964.26M INR in the quarter ending December 31, 2025, a decrease of -27.93%. This brings the company's revenue in the last twelve months to 3.91B, down -32.97% year-over-year. In the fiscal year ending March 31, 2025, Aarey Drugs & Pharmaceuticals had annual revenue of 4.74B with 17.73% growth.
Revenue (ttm)
3.91B
Revenue Growth
-32.97%
P/S Ratio
0.41
Revenue / Employee
29.61M
Employees
132
Market Cap
1.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4.74B | 713.61M | 17.73% |
| Mar 31, 2024 | 4.03B | -163.73M | -3.91% |
| Mar 31, 2023 | 4.19B | -739.78M | -15.01% |
| Mar 31, 2022 | 4.93B | 1.42B | 40.27% |
| Mar 31, 2021 | 3.51B | 505.20M | 16.79% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Sigachi Industries | 4.85B |
| Sakar Healthcare | 2.31B |
| Valiant Laboratories | 2.03B |
| Bafna Pharmaceuticals | 1.47B |
| Alpa Laboratories | 1.14B |
| Vaishali Pharma | 1.14B |
| Par Drugs and Chemicals | 1.06B |